ID: ALA4060165

Max Phase: Preclinical

Molecular Formula: C12H15BrClNO2

Molecular Weight: 284.15

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cl.O=C(O)[C@@H]1C[C@@H](Cc2ccccc2Br)CN1

Standard InChI:  InChI=1S/C12H14BrNO2.ClH/c13-10-4-2-1-3-9(10)5-8-6-11(12(15)16)14-7-8;/h1-4,8,11,14H,5-7H2,(H,15,16);1H/t8-,11+;/m1./s1

Standard InChI Key:  FSCTVRPHDYFEBA-NINOIYOQSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 284.15

Molecular Weight (Monoisotopic): 283.0208

AlogP: 2.05

#Rotatable Bonds: 3

Polar Surface Area: 49.33

Molecular Species: ZWITTERION

HBA: 2

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 3

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 1.09

CX Basic pKa: 11.45

CX LogP: 0.14

CX LogD: 0.14

Aromatic Rings: 1

Heavy Atoms: 16

QED Weighted: 0.89

Np Likeness Score: 0.32

References

1.  (2014)  D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disorders, 

2. Singh K, Tanui R, Gameiro A, Eisenberg G, Colas C, Schlessinger A, Grewer C..  (2017)  Structure activity relationships of benzylproline-derived inhibitors of the glutamine transporter ASCT2.,  27  (3): [PMID:28057420] [10.1016/j.bmcl.2016.12.063]

Source

Source(2):

• Scientific Literature
• Patent Bioactivity Data